Zevra Therapeutics (ZVRA) Times Interest Earned (2014 - 2026)
Zevra Therapeutics' (ZVRA) quarterly Times Interest Earned came in at $30.48 in Q1 2026, up 3413.7% YoY from $0.87 in Q1 2025, and up 391.85% on a QoQ basis from -$10.44 in Q4 2025.
Powered by 
Analysis
Zevra Therapeutics (ZVRA) Times Interest Earned (2014 - 2026) Analysis & Trends
Zevra Therapeutics (ZVRA) has 13 years of Times Interest Earned data on file, last reported at $30.48 in Q1 2026.
- Quarterly Times Interest Earned rose 3413.7% year-over-year to $30.48 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.11 (up 90.96% YoY) and the FY2025 annual result came in at -$0.69, down 15.72% from the prior year.
- Times Interest Earned rose to $30.48 in Q1 2026, from -$10.44 in the prior quarter.
- In the past five years, Times Interest Earned ranged from a high of $30.48 in Q1 2026 to a low of -$54.78 in Q4 2022.
- A 5-year average of -$13.19 and a median of -$10.06 in 2023 frame the typical range for Times Interest Earned.
- Annual changes were most pronounced in 2023 — Times Interest Earned sank 914.93% — and 2026, when it soared 3413.7%.
- Tracing ZVRA's Times Interest Earned over 5 years: stood at -$54.78 in 2022, then jumped by 73.52% to -$14.5 in 2023, then jumped by 51.56% to -$7.03 in 2024, then plunged by 48.62% to -$10.44 in 2025, then jumped by 391.85% to $30.48 in 2026.
- The last three Times Interest Earned figures came in at $30.48 (Q1 2026), -$10.44 (Q4 2025), and $2.02 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -493.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -21.24 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.18 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2.82 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 1.42 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.08 |
| 10 | Zevra Therapeutics | 734.60 Mn | 513.03 Mn | 38.18 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 30.48 |
| Dec 31, 2025 | 4.78 |
| Sep 30, 2025 | 2.02 |
| Jun 30, 2025 | -35.36 |
| Mar 31, 2025 | -2.72 |
| Dec 31, 2024 | -7.03 |
| Sep 30, 2024 | -11.81 |
| Jun 30, 2024 | -11.28 |
| Mar 31, 2024 | -27.87 |
| Dec 31, 2023 | -20.05 |
| Sep 30, 2023 | -41.98 |
| Jun 30, 2023 | -31.74 |
| Mar 31, 2023 | -70.50 |
| Dec 31, 2022 | -54.78 |
| Sep 30, 2022 | -53.44 |
| Jun 30, 2022 | -687.97 |
| Mar 31, 2022 | -371.80 |
| Dec 31, 2021 | -568.40 |
| Sep 30, 2021 | -370.33 |
| Jun 30, 2021 | 364.56 |